<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">nnp</journal-id><journal-title-group><journal-title xml:lang="en">Neurology, Neuropsychiatry, Psychosomatics</journal-title><trans-title-group xml:lang="ru"><trans-title>Неврология, нейропсихиатрия, психосоматика</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2074-2711</issn><issn pub-type="epub">2310-1342</issn><publisher><publisher-name>"IMA-Press", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/2074-2711-2019-3S-78-81</article-id><article-id custom-type="elpub" pub-id-type="custom">nnp-1137</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group></article-categories><title-group><article-title>Atherothrombotic stroke in non-valvular atrial fibrillation</article-title><trans-title-group xml:lang="ru"><trans-title>Атеротромботический инсульт при неклапанной фибрилляции предсердий</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Явелов</surname><given-names>И. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Yavelov</surname><given-names>I. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>101990, Москва, Петроверигский пер., 10, стр. 3</p></bio><bio xml:lang="en"><p>10, Petroverigsky Lane, Build. 3, Moscow 101990</p></bio><email xlink:type="simple">yavelov@yahoo.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Окшина</surname><given-names>Е. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Okshina</surname><given-names>E. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>101990, Москва, Петроверигский пер., 10, стр. 3</p></bio><bio xml:lang="en"><p>10, Petroverigsky Lane, Build. 3, Moscow 101990</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «Национальный медицинский исследовательский центр профилактической медицины» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Center of Preventive Medicine, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>24</day><month>06</month><year>2019</year></pub-date><volume>11</volume><issue>3S</issue><issue-title>Спецвыпуск: когнитивные нарушения, цереброваскулярные заболевания</issue-title><fpage>78</fpage><lpage>81</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Yavelov I.S., Okshina E.Y., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Явелов И.С., Окшина Е.Ю.</copyright-holder><copyright-holder xml:lang="en">Yavelov I.S., Okshina E.Y.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://nnp.ima-press.net/nnp/article/view/1137">https://nnp.ima-press.net/nnp/article/view/1137</self-uri><abstract><p>The review analyzes data on the detection rate of and the abilities to predict and prevent non-cardioembolic strokes in non-valvular atrial fibrillation. According to accumulated facts, vitamin K antagonists in non-valvular atrial fibrillation are noted to be inferior to antiplatelet drugs in efficiency in preventing non-cardioembolic (atherothrombotic in particular) strokes, and the widespread use of oral anticoagulants in combination with antiplatelet drugs does not generally reduce the incidence of poor outcomes, markedly increasing the risk of serious bleeding. Nevertheless, it is conceivable that this combination antithrombotic therapy may be useful for certain categories of patients at the highest risk for atherothrombotic stroke and at relatively low risk for hemorrhagic complications. Cohorts of patients, to whom such an approach should be reasonable considered to be applied, have not yet been identified.</p></abstract><trans-abstract xml:lang="ru"><p>В обзоре анализируются данные о частоте выявления, возможностях прогнозирования и профилактики некардиоэмболических инсультов при неклапанной фибрилляции предсердий. Отмечено, что, согласно накопленным фактам, при неклапанной фибрилляции предсердий антагонисты витамина К уступают антиагрегантам в том, что касается эффективности профилактики некардиоэмболических (в частности, атеротромботических) инсультов, а широкое использование сочетания пероральных антикоагулянтов с антиагрегантами в целом не способствует снижению частоты неблагоприятных исходов, заметно увеличивая риск серьезных кровотечений. Тем не менее не исключено, что подобная комбинированная антитромботическая терапия сможет оказаться полезной отдельным категориям больных с наиболее высоким риском атеротромботического инсульта и относительно невысокой опасностью геморрагических осложнений. Контингенты больных, у которых разумно рассматривать подобный подход, пока не определены.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>инсульт</kwd><kwd>ишемический инсульт</kwd><kwd>некардиоэмболический инсульт</kwd><kwd>атеротромботический инсульт</kwd><kwd>фибрилляция предсердий</kwd><kwd>пероральные антикоагулянты</kwd><kwd>ацетилсалициловая кислота</kwd></kwd-group><kwd-group xml:lang="en"><kwd>stroke</kwd><kwd>ischemic stroke</kwd><kwd>non-cardioembolic stroke</kwd><kwd>atherothrombotic stroke</kwd><kwd>atrial fibrillation</kwd><kwd>oral anticoagulants</kwd><kwd>acetylsalicylic acid</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893-962. doi: 10.1093/eurheartj/ehw210</mixed-citation><mixed-citation xml:lang="en">Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893-962. doi: 10.1093/eurheartj/ehw210</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. JACC. 2019. doi: 10.1016/j.jacc.2019.01.011</mixed-citation><mixed-citation xml:lang="en">January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. JACC. 2019. doi: 10.1016/j.jacc.2019.01.011</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Kim YD, Cha MJ, Kim J, et al. Increases in cerebral atherosclerosis according to CHADS2 scores in patients with stroke with nonvalvular atrial fibrillation. Stroke. 2011;42:930-4. doi: 10.1161/STROKEAHA.110.602987</mixed-citation><mixed-citation xml:lang="en">Kim YD, Cha MJ, Kim J, et al. Increases in cerebral atherosclerosis according to CHADS2 scores in patients with stroke with nonvalvular atrial fibrillation. Stroke. 2011;42:930-4. doi: 10.1161/STROKEAHA.110.602987</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Arboix A, Garcia-Eroles L, Massons JB, et al. Atrial fibrillation and stroke: clinical presentation of cardioembolic versus atherothrombotic infarction. Int J Cardiol. 2000;73:33-42. doi: 10.1016/S0167-5273(99)00214-4</mixed-citation><mixed-citation xml:lang="en">Arboix A, Garcia-Eroles L, Massons JB, et al. Atrial fibrillation and stroke: clinical presentation of cardioembolic versus atherothrombotic infarction. Int J Cardiol. 2000;73:33-42. doi: 10.1016/S0167-5273(99)00214-4</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Benbir G, Uluduz D, Ince B, Bozluolcay M. Atherothrombotic ischemic stroke in patients with atrial fibrillation. Clin Neurol Neurosurg. 2007;109:485-90. doi: 10.1016/j.clineuro.2007. 03.009</mixed-citation><mixed-citation xml:lang="en">Benbir G, Uluduz D, Ince B, Bozluolcay M. Atherothrombotic ischemic stroke in patients with atrial fibrillation. Clin Neurol Neurosurg. 2007;109:485-90. doi: 10.1016/j.clineuro.2007. 03.009</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Bogousslavsky J, van Melle G, Regli F, Kappenberger L. Pathogenesis of anterior circulation stroke in patients with nonvalvular atrial fibrillation: the Lausanne Stroke Registry. Neurology. 1990;40:1046-50. doi: 10.1212/WNL.40.7.1046</mixed-citation><mixed-citation xml:lang="en">Bogousslavsky J, van Melle G, Regli F, Kappenberger L. Pathogenesis of anterior circulation stroke in patients with nonvalvular atrial fibrillation: the Lausanne Stroke Registry. Neurology. 1990;40:1046-50. doi: 10.1212/WNL.40.7.1046</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Hart RG, Pearce LA, Miller VT, et al. Cardioembolic vs. noncardioembolic strokes in atrial fibrillation: frequency and effect of antithrombotic agents in the stroke prevention in atrial fibrillation studies. Cerebrovasc Dis. 2000;10:39-43. doi: 10.1159/000016023</mixed-citation><mixed-citation xml:lang="en">Hart RG, Pearce LA, Miller VT, et al. Cardioembolic vs. noncardioembolic strokes in atrial fibrillation: frequency and effect of antithrombotic agents in the stroke prevention in atrial fibrillation studies. Cerebrovasc Dis. 2000;10:39-43. doi: 10.1159/000016023</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Chang YJ, Ryu SJ, Lin SK. Carotid artery stenosis in ischemic stroke patients with nonvalvular atrial fibrillation. Cerebrovasc Dis. 2002; 13:16-20. doi: 10.1159/000047740</mixed-citation><mixed-citation xml:lang="en">Chang YJ, Ryu SJ, Lin SK. Carotid artery stenosis in ischemic stroke patients with nonvalvular atrial fibrillation. Cerebrovasc Dis. 2002; 13:16-20. doi: 10.1159/000047740</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Park YS, Chung PW, Kim YB, et al. Small deep infarction in patients with atrial fibrillation: evidence of lacunar pathogenesis. Cerebrovasc Dis. 2013;36:205-10. doi: 10.1159/000353736</mixed-citation><mixed-citation xml:lang="en">Park YS, Chung PW, Kim YB, et al. Small deep infarction in patients with atrial fibrillation: evidence of lacunar pathogenesis. Cerebrovasc Dis. 2013;36:205-10. doi: 10.1159/000353736</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Evans A, Perez I, Yu G, Kalra L. Secondary stroke prevention in atrial fibrillation: lessons from clinical practice. Stroke. 2000;31:2106-11. doi: 10.1161/01.STR.31.9.2106</mixed-citation><mixed-citation xml:lang="en">Evans A, Perez I, Yu G, Kalra L. Secondary stroke prevention in atrial fibrillation: lessons from clinical practice. Stroke. 2000;31:2106-11. doi: 10.1161/01.STR.31.9.2106</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Evans A, Perez I, Yu G, Kalra L. Should stroke subtype influence anticoagulation decisions to prevent recurrence in stroke patients with atrial fibrillation? Stroke. 2001;32:2828-32. doi: 10.1161/hs1201.099520</mixed-citation><mixed-citation xml:lang="en">Evans A, Perez I, Yu G, Kalra L. Should stroke subtype influence anticoagulation decisions to prevent recurrence in stroke patients with atrial fibrillation? Stroke. 2001;32:2828-32. doi: 10.1161/hs1201.099520</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Katsi V, Georgiopoulos G, Skafida A, et al. Noncardioembolic stroke in patients with atrial fibrillation. Angiology. 2019;70:299-304. doi: 10.1177/0003319718791711</mixed-citation><mixed-citation xml:lang="en">Katsi V, Georgiopoulos G, Skafida A, et al. Noncardioembolic stroke in patients with atrial fibrillation. Angiology. 2019;70:299-304. doi: 10.1177/0003319718791711</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Cano LM, Cardona P, Quesada H, et al. Ischaemic stroke in patients treated with oral anticoagulants. Neurologia. 2016;31:395-400. doi: 10.1016/j.nrl.2014.09.010</mixed-citation><mixed-citation xml:lang="en">Cano LM, Cardona P, Quesada H, et al. Ischaemic stroke in patients treated with oral anticoagulants. Neurologia. 2016;31:395-400. doi: 10.1016/j.nrl.2014.09.010</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Hwang J, Chung J-W, Lee MJ, et al. Implications of CHA2DS2-VASc Score in Stroke Patients with Atrial Fibrillation: An Analysis of 938 Korean Patients. Eur Neurol. 2017;77:307- 15. doi: 10.1159/000475495</mixed-citation><mixed-citation xml:lang="en">Hwang J, Chung J-W, Lee MJ, et al. Implications of CHA2DS2-VASc Score in Stroke Patients with Atrial Fibrillation: An Analysis of 938 Korean Patients. Eur Neurol. 2017;77:307- 15. doi: 10.1159/000475495</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Kim SJ, Ryoo S, Kwon S, et al. Is atrial fibrillation always a culprit of stroke inpatients with atrial fibrillation plus stroke? Cerebrovasc Dis. 2013;36:373-82. doi: 10.1159/000355571</mixed-citation><mixed-citation xml:lang="en">Kim SJ, Ryoo S, Kwon S, et al. Is atrial fibrillation always a culprit of stroke inpatients with atrial fibrillation plus stroke? Cerebrovasc Dis. 2013;36:373-82. doi: 10.1159/000355571</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Cha M-J, Kim YD, Nam HS, et al. Stroke mechanism in patients with non-valvular atrial fibrillation according to the CHADS2 and CHA2DS2-VASc scores. Eur J Neurol. 2012; 19:473-9. doi: 10.1111/j.1468-1331.2011.03547.x</mixed-citation><mixed-citation xml:lang="en">Cha M-J, Kim YD, Nam HS, et al. Stroke mechanism in patients with non-valvular atrial fibrillation according to the CHADS2 and CHA2DS2-VASc scores. Eur J Neurol. 2012; 19:473-9. doi: 10.1111/j.1468-1331.2011.03547.x</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Yang P-S, Pak H-N, Park D-H, et al. Noncardioembolic risk factors in atrial fibrillationassociated ischemic stroke. PLoS ONE. 2018; 13:e0201062. doi: 10.1371/journal.pone.0201062</mixed-citation><mixed-citation xml:lang="en">Yang P-S, Pak H-N, Park D-H, et al. Noncardioembolic risk factors in atrial fibrillationassociated ischemic stroke. PLoS ONE. 2018; 13:e0201062. doi: 10.1371/journal.pone.0201062</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Bekwelem W, Jensen PN, Norby FL, et al. Carotid atherosclerosis and stroke in atrial fibrillation: the atherosclerosis risk in Communities study. Stroke. 2016;47:1643-46. doi: 10.1161/STROKEAHA.116.013133</mixed-citation><mixed-citation xml:lang="en">Bekwelem W, Jensen PN, Norby FL, et al. Carotid atherosclerosis and stroke in atrial fibrillation: the atherosclerosis risk in Communities study. Stroke. 2016;47:1643-46. doi: 10.1161/STROKEAHA.116.013133</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Paciaroni M, Agnelli G, Ageno W, et al. Risk factors for cerebral ischemic events in patients with atrial fibrillation on warfarin for stroke prevention. Atherosclerosis. 2010;212:564-6. doi: 10.1016/j.atherosclerosis.2010.06.016</mixed-citation><mixed-citation xml:lang="en">Paciaroni M, Agnelli G, Ageno W, et al. Risk factors for cerebral ischemic events in patients with atrial fibrillation on warfarin for stroke prevention. Atherosclerosis. 2010;212:564-6. doi: 10.1016/j.atherosclerosis.2010.06.016</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Miller VT, Pearce LA, Feinberg WM, et al. Differential effect of aspirin versus warfarin on clinical stroke types in patients with atrial fibrillation. Stroke prevention in atrial fibrillation investigators. Neurology. 1996;46:238-40. doi: 10.1212/WNL.46.1.238</mixed-citation><mixed-citation xml:lang="en">Miller VT, Pearce LA, Feinberg WM, et al. Differential effect of aspirin versus warfarin on clinical stroke types in patients with atrial fibrillation. Stroke prevention in atrial fibrillation investigators. Neurology. 1996;46:238-40. doi: 10.1212/WNL.46.1.238</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Becattini C, Dentali F, Camporese G, et al. Carotid atherosclerosis and risk for ischemic stroke in patients with atrial fibrillation on oral anticoagulant treatment. Atherosclerosis. 2018; 271:177-81. doi: 10.1016/j.atherosclerosis.2018.02.004</mixed-citation><mixed-citation xml:lang="en">Becattini C, Dentali F, Camporese G, et al. Carotid atherosclerosis and risk for ischemic stroke in patients with atrial fibrillation on oral anticoagulant treatment. Atherosclerosis. 2018; 271:177-81. doi: 10.1016/j.atherosclerosis.2018.02.004</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Lane DA, Raichand S, Moore D, et al. Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review. Health Technol Assess. 2013; 17(30). doi: 10.3310/hta17300</mixed-citation><mixed-citation xml:lang="en">Lane DA, Raichand S, Moore D, et al. Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review. Health Technol Assess. 2013; 17(30). doi: 10.3310/hta17300</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Kumar S, Danik SB, Altman RK, et al. NonVKA Oral Anticoagulants and Antiplatelet Therapy for Stroke Prevention in Patients with Atrial Fibrillation: a Meta-analysis of Randomized Controlled Trials. Cardiol Rev. 2016;24: 218-23. doi: 10.1097/CRD.0000000000000088</mixed-citation><mixed-citation xml:lang="en">Kumar S, Danik SB, Altman RK, et al. NonVKA Oral Anticoagulants and Antiplatelet Therapy for Stroke Prevention in Patients with Atrial Fibrillation: a Meta-analysis of Randomized Controlled Trials. Cardiol Rev. 2016;24: 218-23. doi: 10.1097/CRD.0000000000000088</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Masunaga N, Abe M, Ogawa H, et al. Current Status, Time Trends and Outcomes of Combination Therapy With Oral Anticoagulant and Antiplatelet Drug in Patients With Atrial Fibrillation. The Fushimi AF Registry. Circ J. 2018;82:2983-91. doi: 10.1253/circj.CJ-18-0872</mixed-citation><mixed-citation xml:lang="en">Masunaga N, Abe M, Ogawa H, et al. Current Status, Time Trends and Outcomes of Combination Therapy With Oral Anticoagulant and Antiplatelet Drug in Patients With Atrial Fibrillation. The Fushimi AF Registry. Circ J. 2018;82:2983-91. doi: 10.1253/circj.CJ-18-0872</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Steinberg BA, Kim S, Piccini JP, et al. Use and Associated Risks of Concomitant Aspirin Therapy with Oral Anticoagulation in Patients with Atrial Fibrillation: Insights from the ORBIT-AF Registry. Circulation. 2013;128:721-8. doi: 10.1161/CIRCULATIONAHA.113.002927</mixed-citation><mixed-citation xml:lang="en">Steinberg BA, Kim S, Piccini JP, et al. Use and Associated Risks of Concomitant Aspirin Therapy with Oral Anticoagulation in Patients with Atrial Fibrillation: Insights from the ORBIT-AF Registry. Circulation. 2013;128:721-8. doi: 10.1161/CIRCULATIONAHA.113.002927</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Olesen JB, Lip GYH, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thromb Haemost. 2011;106:739-49. doi: 10.1160/TH11-05-0364</mixed-citation><mixed-citation xml:lang="en">Olesen JB, Lip GYH, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thromb Haemost. 2011;106:739-49. doi: 10.1160/TH11-05-0364</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Nakamura A, Kuroda J, Ago T, et al. Causes of Ischemic Stroke in Patients with Non-Valvular Atrial Fibrillation. Cerebrovasc Dis. 2016;42: 196-204. doi: 10.1159/000445723</mixed-citation><mixed-citation xml:lang="en">Nakamura A, Kuroda J, Ago T, et al. Causes of Ischemic Stroke in Patients with Non-Valvular Atrial Fibrillation. Cerebrovasc Dis. 2016;42: 196-204. doi: 10.1159/000445723</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. NEJM. 2017;377:1319-30. doi: 10.1056/NEJMoa1709118</mixed-citation><mixed-citation xml:lang="en">Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. NEJM. 2017;377:1319-30. doi: 10.1056/NEJMoa1709118</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Sharma M, Hart RG, Connolly SJ, et al. Stroke Outcomes in the COMPASS Trial. Circulation. 2019;139:1134-45. doi: 10.1161/ CIRCULATIONAHA.118.035864</mixed-citation><mixed-citation xml:lang="en">Sharma M, Hart RG, Connolly SJ, et al. Stroke Outcomes in the COMPASS Trial. Circulation. 2019;139:1134-45. doi: 10.1161/ CIRCULATIONAHA.118.035864</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
